ArchiveSeptember 2018

DMF inhibiting B cells numbers

  Times are a changing folks.  Not a year ago the same type of phenotpying data was reported in the blood of people treated with DMF.  The focus has now changed, guess where. B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate. Høglund RA, Polak J, Vartdal F, Holmøy T, Lossius A. Mult Scler Relat Disord. 2018 Sep 6;26:90-95...

Treating Fatigue with Stem Cells

  Fatigue is the symptom which has been high on the agenda for research into its cause and cure. It seems this is a sickness behaviour as a consequence of inflammation within the CNS. It is probable that it is caused, at least in part, by inflammatory cytokines. Therefore, if you get rid of inflammation, fatigue may be reduced. We first saw this with natalizumab and so it is the cases...

ECTRIMS 2018… here we go again!

In little over 2 weeks’ time, the MS professional community will travel to Berlin for the 34th ECTRIMS meeting. It’s the largest European conference focusing on MS research and treatment, and is attended by MS healthcare professionals, companies, researchers and charities.   Similar to previous years, the Barts-MS team are keen to get some of this new research out to you as quickly as...

Guest Post: The Real, Real Deal with Exercising and MS

Oh no. No, no, no, you’re thinking. Not another Barts MS Blog lecture on the importance of exercising when you have multiple sclerosis. Especially a guest blog from that Dave guy who runs ActiveMSers.org and who thinks he is funny and has no professional medical or physical fitness credentials—just a dude who runs a blog, ruffles feathers like Gavin, and works out. I get it. I mean, I could point...

And the risk-sharing scheme results…

J Neurol Neurosurg Psychiatry. 2018 Sep 21. pii: jnnp-2018-318360. doi: 10.1136/jnnp-2018-318360. [Epub ahead of print] Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme. Palace J, Duddy M, Lawton M, Bregenzer T, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H...

Is EAE a valid tool if studying MS

Mouse EAEers currently use myelin oligodendrocyte glycoprotein to induce disease, with which to study MS. However, do people with MS respond to this protein Papp V, Langkilde AR, Blinkenberg M, Schreiber K, Jensen PEH, Sellebjerg F. Clinical utility of anti-MOG antibody testing in a Danish cohort. Mult Scler Relat Disord. 2018 Sep 11;26:61-67. doi: 10.1016/j.msard.2018.09.010. [Epub...

The Scottish MS Register Annual Report – 2018

The Scottish MS Register (SMSR) has been collecting data on everyone with a confirmed diagnosis of MS in Scotland since the year 2010. Unfortunately, Scotland has one of the highest rates of MS in the world. The Scottish MS register was set up to count people newly diagnosed with MS, to help monitor service quality and to plan future services for people with MS. Since it started, the Scottish...

CCSVI2..Don’t Do it.

  Messing about with suspected blocked blood vessels led to the CCSVI movement, that was discredited by science,    So yesterday we had the media suggesting that you should block a different vessel in the brain to get rid of MS.    One of the readers asked whether this is the beginning of CCSVI2    It was claimed that a “Team identifies brain’s lymphatic vessels as new avenue to...

Copaxone, why is is not so effective?

I think Glatiramer acetate (at the population level) is a low efficacy treatment. What supports this? Besides the clinical efficacy we have this Pavelek Z, Vyšata O, Sobíšek L, Klímová B, Andrýs C, Vokurková D, Mazurová R, Štourač P, Vališ M. Lymphocyte populations and their change during five-year glatiramer acetate treatment. Neurol Neurochir Pol. 2018 Aug 18. pii: S0028-3843(18)30179-8. doi:...

Real-world experience on first line oral therapies DMF and teriflunomide

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience E D’Amico, A Zanghì, G Callari, G Borriello, A Gallo, G Graziano, P Valentino, M Buccafusca, S Cottone, G Salemi, P Ragonese, R B Bossio, R Docimo, L M E Grimaldi, C Pozzilli, G Tedeschi, M Zappia, F Patti Ther Adv Neurol Disord...

Translate

Categories

Recent Posts

Recent Comments

Archives